Pegfilgrastim biosimilar - NAL Pharma

Drug Profile

Pegfilgrastim biosimilar - NAL Pharma

Alternative Names: NAL 3760; PEG-GCSF - NAL Pharma

Latest Information Update: 12 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NAL Pharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neutropenia

Most Recent Events

  • 11 Aug 2016 Pegfilgrastim biosimilar - NAL Pharma is available for licensing as of 11 Aug 2016. http://www.nalpharma.com/aboutUs.php?id=2&lang=en
  • 11 Aug 2016 Preclinical trials in Neutropenia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top